Imaging Mass Cytometry and Single-Cell Genomics Reveal Differential Depletion and Repletion of B-Cell Populations Following Ofatumumab Treatment in Cynomolgus Monkeys

Ofatumumab is the first, fully human, anti-CD20 monoclonal antibody in Phase 3 development for multiple sclerosis (MS). The study focused on changes in lymphocyte subsets in blood and lymphoid tissues and on potential novel biomarkers as a result of anti-CD20 antibody action in Cynomolgus monkeys tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Theil, Diethilde, Smith, Paul, Huck, Catherine, Gilbart, Yoann, Kakarieka, Algirdas, Leppert, David, Rauld, Celine, Schmid, Cindy, Baumgartner, Reto, Stuber, Nathalie, Cordoba, Francisco, Dubost, Valerie, Darribat, Katy, Jivkov, Magali, Frieauff, Wilfried, Kneuer, Rainer, Stoeckli, Markus, Reinker, Stefan, Mansfield, Keith, Carballido, José M., Couttet, Philippe, Weckbecker, Gisbert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6596277/
https://www.ncbi.nlm.nih.gov/pubmed/31281311
http://dx.doi.org/10.3389/fimmu.2019.01340

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6596277/
https://www.ncbi.nlm.nih.gov/pubmed/31281311
http://dx.doi.org/10.3389/fimmu.2019.01340

Ejemplares similares